|
Archive Course Catalog
Browse archived online courses and resources.
|
 | This course is no longer available for credit.
Published: March 1, 2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Basic Principles will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: March 1, 2022 - March 1, 2023
Estimated time to complete activity: 45 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify key biological concepts of immunotherapy
- Describe the various types of immunotherapy
- Describe how biomakers play a key role in immunotherapy
- Describe how to assess the patient response to immunotherapy
Faculty
Stefani Spranger, PhD
Assistant Professor of Biology
The Koch Institue for Integrative Cancer Research, Massachusetts Institue of Technology
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Stefani Spranger, PhD: Consulting Fees: Arcus, Tango, Takeda, Ribon, Merck, Dragonfly.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-081-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: July 01, 2021
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published 11/1/2021
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials dealing with all three cancer types are discussed, as are key findings that have resulted in recent FDA approvals. Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for these cancers.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: November 1, 2021 - November 1, 2022
Estimated time to complete activity: 30 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Implement cancer immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer.
- Identify clinical trials relating to these cancers, as well as the FDA-approved treatments for each.
- Describe the rationale for common approaches to cancer immunotherapy.
Faculty
Mehmet Asim Bilen, MD
Genitourinary Medical Oncologist
Emory University, Atlanta, GA
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Mehmet Asim Bilen, MD - Consulting Fees: Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, and Sanofi; Grants to the institution - Xencor, Bayer, Bristol-Myers Squibb, Genetech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 11/1/2021 through 11/1/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.2 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-3074-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: July 01, 2021
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published: 3/1/2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Gastrointestinal Cancers, provides an overview of immunotherapy treatment for hepatocellular, colorectal, and other gastrointestinal malignancies. Multiple clinical trials dealing with these types of cancer are discussed, as are key findings that have resulted in recent FDA approvals. Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for gastrointestinal cancers.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: March 1, 2022 - March 1, 2023
Estimated time to complete activity: 30 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Implement cancer immunotherapy treatment for gastrointestinal cancer.
- Identify various studies that are stil ongoing as well as completed clinical trials which have resulted in approvals by disease state.
- Describe the rationale for common approaches to cancer immunotherapy.
Faculty
Aiwu Ruth He, MD, PhD
Associate Professor of Medicine, Medstar Georgetown University Hospital
Georgetown University
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Aiwu Ruth He, MD, PhD: Consulting Fees: Merck, Bayer, BMS, Aztrazeneca; Fees for Non-CE Service: Eisai, BMS, Exelixis; Contracted Research: Merck, Genentech
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-082-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: July 01, 2021
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published 10/07/2021
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutational Burden-High Cancers, provides an overview of immunotherapy treatment for cancers with these characteristics. This course will help the learner understand what microsatellite instability (MSI) and tumor mutational burden (TMB) terms mean, what meaures can be performed to identify MSI/TMB, various FDA-approved regimens for cancers that are MSI/TMB-high, and provide current clinical trial information. Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy for the treatment of cancers with high or low microsatellite instability and/or tumor mutational burden.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: October 7, 2021 - October 7, 2022
Estimated time to complete activity: 30 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Define the meaning of microsatellite instability and tumor mutational burden.
- Identify the methods used to measure MSI or TMB.
- Describe the rationale for common approaches to cancer immunotherapy with MSI/TMB measures identified.
Faculty
Dung Le, MD
Associate Professor, GI Medical Oncology
Sydney Kimmel Cancer Care Center, Johns Hopkins University
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Dung Le, MD: Consulting Fees: Merck, Bristol Myers Squibb, Janssen, Nouscom. Contracted Research: Merck, Bristol Myers Squibb, Aduro Biotech, Medivir, Curegenix, Nouscom
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 10/7/2021 through 10/7/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-3027-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: July 01, 2021
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published March 1, 2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
In this course, Toxicity Management, learners will be given information on the incidence, onset, severity and grading of immune-related toxicities; as well as immune-related adverse events with immune checkpoint inhibitors. Dr. Jarushka Naidoo will also discuss cellular therapy adverse events and their management and discuss immunotherapy in special patient populations.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: March , 2022 - March 1, 2023
Estimated time to complete activity: 45 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify immune-related toxicities by grade, onset, and incidence.
- Identify immune-related adverse events resulting from immune checkpoint inhibitors.
- Describe the adverse events and management of cellular therapies.
- Describe the precautions needed when immunotherapy is provided to special patient populations.
Faculty
Jarushka Naidoo, MBBCh
Assistant Professor of Oncology and Attending Physician
Sydney Kimmel Cancer Center, Johns Hopkins University
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Jarushka Naidoo, MBBCh: Consulting Fees: Astrazeneca, Bristol Meyers-Squibb, Roche/Genetech. Non-CME Services: Merck, Bristol Myers-Squibb, Astrazeneca. Contracted Research: Astrazeneca, Merck.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162 - 9999-22-083-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: July 01, 2021
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published 04/25/2022
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Skin Cancers, provides an overview of immunotherapy treatment for various forms of skin cancer. Multiple clinical trials are discussed, as are key findings that have resulted in recent FDA approvals. Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancer.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: April 25, 2022 - April 25, 2023
Estimated time to complete activity: 45 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Implement cancer immunotherapy treatment for skin cancer.
- Identify FDA-approved immunotherapy treatments for skin cancer.
- Describe the rationale for common approaches to cancer immunotherapy.
Faculty
Shailender Bhatia, MD
Associate Professor of Medical Oncology
University of Washington
Fred Hutchison Cancer Research Center, Seattle, WA
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Shailender Bhatia, MD: Consulting Fees: Genentech, BMS, EMD-Serono, Sanofi-Genzyme, Exicure. Contracted research: BMS, EMD-Serono, Immune Design, Merck, Novartis, Oncosec, Nantkwest, Exicure, Nektar, CheckMate, Xencor, Trisalus.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 04/25/2022 through 04/25/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-22-235-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: July 01, 2021
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published 6/25/2021
Course description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides an overview of the various treatment approaches to hematologic malignancies. This module will provide an overview of the major immunotherapies in development, FDA-approved treatments as well as the side effects associated with those treatments, and current clinical trials. Learners will have an opportunity to apply what they've learned through two case studies. By the end of the course, participants will be better able to implement immunotherapy for the treatment of hematologic malignancies.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: June 25, 2021 - June 25, 2022
Estimated time to complete activity: 45 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Discuss the purpose of immune checkpoint inihibitors, as well as identify which have been approved by the FDA.
- Recognize antibody-drug conjugates (ADCs), which have been FDA-approved, and appropriate malignancies for which ADCs would be effective.
- Identify bispecific antigens' role in immunotherapy.
- Describe cellular therapies, including CAR T cell therapies and the side effects, current FDA approvals, and clinical trials in development.
Faculty
Hongtao Liu, MD, PhD
Associate Professor of Medicine
Co-Director, Combined Apheresis Unit
Medical Director, Clinical Cellular Labratory Section of Hematology/Oncology
Department of Medicine, University of Chicago
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Hongtao Liu, MD, PhD - Consulting Fees: Agios Pharmaceuticals; BeiGene, NGM Biopharmarmaceuticals. Contracted Research: BMS; Karyopharm, Miltenyi.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 6/25/2021 through 6/25/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2839-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: June 23, 2021
On-Demand Release Date: Available Now | Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published July 28, 2021
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, What's Next in Cancer Immunotherapy, provides an overview of several publications researching the conditions and stresses of the tumor microenvironment, as well as discussing some of the major factors impacting those providing and receiving immunotherapy treatments. At the end of this course, participants have a better understanding not only of stress sensor impacting tumor cell growth, but also some of the major hurdles affecting immunotherapy's progression.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: July 28, 2021 - July 28, 2022
Estimated time to complete activity: 45 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify three stress sensors impacting the endoplasmic reticulum.
- Explain why targeting the cell's response to these stress sensors may be the key to immunotherapy treatments.
- Identify several of the major hurdles impacting current and future cancer immunotherapy.
Faculty
Jessica Thaxton, PhD, MsCR
Assistant Professor
Hollings Cancer Center, Medical University of South Carolina
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Jessica Thaxton, PhD, MsCR: Research grants TEVA Pharmaceuticals
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 7/28/2021 through 7/28/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2862-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: May 25, 2021
On-Demand Release Date: Available Now | Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Originial publish date: May 21, 2021
PLEASE NOTE: This course is no longer available for CE credit. To see a list of courses available for credit, please click HERE for a complete listing.
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals. Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: May 21, 2021 - May 21, 2022
Estimated time to complete activity: 45 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Implement cancer immunotherapy treatment for lung cancer.
- Identify immune-related toxicities related to lung cancer immunotherapy agents.
- Describe the rationale for common approaches to cancer immunotherapy.
Faculty
Jennifer Carlisle, MD
Assistant Professor
Emory University
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity:
Jennifer Carlisle, MD: Nothing to disclose.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 5/21/2021 through 5/21/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2718-H01)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: May 21, 2021
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.75 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Original publish date: May 13, 2021. Please note: this course is no longer available for CE credits.
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at https://www.sitcancer.org/education/aci/online.
This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the currently-approved treatments used to treat both breast and gynecologic cancers, as well as a synopsis of future potential applications of immunotherapy for these cancers. Several clinical trials and two case studies are discussed, allowing the learner to better understand the current use of immunotherapy as well as how clinical trials are leading the way to additional use of immunotherapy for both types of cancer.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Credit Available: May 13, 2021 - May 13, 2022
Estimated time to complete activity: 30 minutes
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
- Select cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
- Describe the rationale for common approaches to cancer immunotherapy
Faculty
Megan Kruse, MD
Associate Staff Physician
Hematology and Medical Oncology
Cleveland Clinic
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Megan Kruse, MD: Consulting Fees: Puma biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly Oncology, Novartis Oncology. Contracted Research: Tempus.
The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose.
Method of Participation and Request for Credit
During the period 5/13/2021 through 5/13/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2714-H01-P)
Type of Activity: Knowledge
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| | Original Course Date: May 13, 2021
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for continuing education credit.
Published February 23, 2021
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Sigrun Hallmeyer, MD
Medical Director, Cancer Service Line
Medical Director, Cancer Survivorship Center
Advocate Lutheran General Hospital
Chair, Executive Committee
Association of Community Cancer Centers, Immuno-Oncology Institute
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting.
- Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: February 23, 2021 - February 23, 2022
Estimated time to complete activity: 1.25 hours
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2606-H01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Sigrun Hallmeyer, MD: Consulting Fees: Bristol Myers Squibb; Cardinal Health; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bristol Myers Squibb
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com.
| | Original Course Date: February 23, 2021
| Approved Credit: : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™ANCC: 1.25 hours Contact HourACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™ACPE: 1.25 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Please note: this course is no longer eligible for continuing education credits.
Published December 24, 2020
Course Description
This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.
Target Audience
This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Pradnya Patil, MD, FACP
Hematology/Oncology Fellow
Taussig Cancer Institute, Cleveland Clinic
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Discuss the mechanisms of peripheral and central immune tolerance.
- Describe the biological pathways involved in mediating autoimmune reactions.
- Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: December 24, 2020 - December 24, 2021
Estimated time to complete activity: 0.5 hour
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2520-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Pradnya Patil, MD, FACP: Nothing to disclose
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com.
| | Original Course Date: December 24, 2020
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.50 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
|
 | This course is no longer available for credit.
Originally published May 26, 2020 (Updated June 9. 2020)
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Anuradha Krishnamurthy, MD
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the characteristics of liver immunobiology
- Implement cancer immunotherapy treatment for HCC and better manage common side effects
- Describe the rationale for common approaches to cancer immunotherapy
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 5/26/20 - 5/26/21
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2142-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Anuradha Krishnamurthy, MD: Nothing to disclose
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: May 26, 2020
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.70 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit.
Published May 26, 2020
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Skin Cancers, provides the latest in immunotherapy treatment for skin cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancers.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Ryan J. Sullivan, MD
Assistant Professor of Medicine
Harvard Medical School, Boston, MA
Division of Hematology/Oncology, Department of Medicine
Massachusetts General Hospital, Boston MA
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the rationale for common approaches to cancer immunotherapy.
- Implement cancer immunotherapy treatment for skin cancers.
- Identify common side effects of immunotherapy agents.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 5/26/20 - 5/26/21
Approximate Time to Complete: 75 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2143-H01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Ryan J. Sullivan, MD: Consulting Fees (Merck, Novartis, Replimune, Bristol Myers Squibb, Asana Biosciences); Contracted Research (Merck, Amgen)
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Skin Cancers.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: May 26, 2020
| Approved Credit: : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™ANCC: 1.30 hours Contact HourACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™ACPE: 1.25 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Originally published April 30, 2020 (updated May 7, 2020)
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancer. Multiple clinical trials are discussed, including both mono- and combination therapies. Learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancer.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Michael Gibson, MD, PhD FACP
Associate Professor of Medicine
Director of Translational Research for Head and Neck Oncology
Director of Translational Therapeutics for Esophago-Gastric Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe rationale for common approaches to cancer immunotherapy.
- Implement cancer immunotherapy treatments for head and neck cancers.
- Identify appropriate clinical management of common side effects of immunotherapy agents.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 4/30/20 - 4/30/21
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2066-H01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Michael Gibson, MD, PhD: Consulting fees to Merck, Bristol-Myers Squibb; Fees for Non-CME/CE services received directly from a commercial interest or their agents to Bristol-Myers Squibb (non-branded)
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 4/30/20 through 4/30/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Head and Neck Cancer.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: April 30, 2020
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.70 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This course is no longer available for credit. Please refer to the newest version of Immunotherapy for the Treatement of Genitourinary Malignancies, published on 11/1/2021.
Originally published March 31, 2020 (updated May 7, 2020)
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for the genitourinary malignancies renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials are discussed, including both mono- and combination therapies. Learners will have an opportunity to interactively apply what they've learned through three case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for genitourinary malignancies.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Pedro Barata, MD, MSc
Assistant Professor of Medicine
Deming Department of Medicine
Section of Hematology/Oncology
Tulane University School of Medicine
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe rationale for common approaches to cancer immunotherapy.
- Implement cancer immunotherapy treatments for genitourinary malignancies.
- Identify appropriate clinical management of common side effects of immunotherapy agents.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 3/31/20 - 3/31/21
Approximate Time to Complete: 1 hour
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2051-H01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Pedro Barata, MD, MSc: Consulting Fees (Exelixis, Caris, Bayer, Janssen, EMD-Serono, Pfizer, Astellas, Dendreon, Clovis, Eisai, Sanofi); Contracted Research (BlueEarth Diagnostics, Nektar, AstraZeneca and Seattle Genetics)
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 3/31/20 through 3/31/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Genitourinary Malignancies.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: March 31, 2020
| Approved Credit: : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ANCC: 1 hour Contact HourACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ACPE: 1 hour Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | This version of the course is no longer available for credit. To access the accredited version, go here to find the What's Next in Cancer Immunotherapy that is a CME-, CPE-, CNE-, and MOC-certified activity.
Published February 11, 2020
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, What's Next for Cancer Immunotherapy?, covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Evan J. Lipson, MD
Associate Professor, Department of Oncology
Johns Hopkins University School of Medicine
Parul Agarwal, MD
Medical Oncology Fellow
Johns Hopkins University School of Medicine
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the rationale behind expanding the settings in which cancer immunotherapy is administered, including patients with a larger variety of tumor types and patient populations previously excluded from clinical trial participation.
- Describe the basis for novel immunotherapy drug combinations.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 2/11/20 - 2/11/21
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-1083-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Evan J. Lipson, MD: Consultant (Bristol-Myers Squibb, Novartis, EMD Serono, Array BioPharma, Macrogenics, Merck); Contracted Research (Bristol-Myers Squibb, Merck)
Parul Agarwal, MD: Nothing to Disclose
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 2/11/20 through 2/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for What's Next for Cancer Immunotherapy?
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: February 11, 2020
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.70 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Access Course
Watch experts discuss the latest data in immunotherapy as well as strategies for managing patients with advanced RCC.
This activity is intended for oncologists, urologists, nephrologists, nurses and nurse practitioners, pharmacists, and other healthcare providers who manage patients with renal cell carcinoma (RCC).
The goal of this activity is to increase understanding of the latest advances in the use of checkpoint inhibition in patients with advanced RCC.
Learning Objectives:
- Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors (ICIs) and other immunotherapies alone or in combination in the treatment of advanced RCC
- Have increased knowledge regarding the impact of recent clinical data on the treatment paradigm for patients with advanced RCC
- Demonstrate greater confidence in their ability to work with the interprofessional team to recognize and mitigate adverse events (AEs) in patients with advanced RCC
Approximate Time to Complete: 30 minutes
Credit Available: Jan. 30, 2020 - Jan. 30, 2021
Developed through a partnership between SITC and Medscape.
Additional Lung Cancer Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)
View Guidelines Here.
View On-demand Webinar Here.
| | Original Course Date: January 30, 2020
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditANCC: 0.50 hours Contact HourACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™ACPE: 0.05 hours Contact Hour
| MORE INFO |
 | Please note this course is no longer available for credit. Click here to access the current version of Immunotherapy for the Treatment of Hematologic Malignancies which is a CME-, CPE-, CNE-, and MOC-certified activity.
Originally published January 23, 2020 (Updated May 7, 2020)
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for hematologic cancers.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Bhagirathbhai R. Dholaria, MBBS
Assistant Professor
Department of Hematology - Oncology
Vanderbilt University School of Medicine, Nashville, TN
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the rationale for common approaches to cancer immunotherapy.
- Implement cancer immunotherapy treatment for hematologic cancers.
- Identify common side effects of immunotherapy agents.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 1/23/20 - 1/23/21
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-1072-H01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Bhagirathbhai R. Dholaria, MBBS: Celgene (consulting)
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/23/20 through 1/23/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hematologic Malignancies.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: January 23, 2020
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.80 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Access Course
Drs Pal and Hammers discuss data and clinical pearls for the use of checkpoint inhibitors in RCC.
This activity is intended for hematologists/oncologists and urologists.
The goal of this activity is to improve knowledge and competence related to the role of immune checkpoint inhibitors (ICIs) as monotherapy and combination therapy for patients with renal cell carcinoma (RCC).
Learning Objectives:
- Have increased knowledge regarding the clinical trial data related to ICIs for the treatment of RCC
- Have greater competence related to selecting patients with RCC who are appropriate candidates to receive ICI therapy
Approximate Time to Complete: 30 minutes
Credit Available: Jan. 21, 2020 - Jan. 21, 2021
Developed through a partnership between SITC and Medscape.
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)
View Guidelines Here.
View On-demand Webinar Here.
| | Original Course Date: January 21, 2020
| Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
| MORE INFO |
 | Published January 16, 2020
Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.
Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Morgan Gwynn, PharmD, BCOP, CPP
Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
University of North Carolina Medical Center
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
- Describe best practices for managing common side effects seen in cancer immunotherapy treatment
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: 1/16/20-1/16/21
Approximate Time to Complete: 45 minutes
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-1068-H01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
Faculty
Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Toxicity Management.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com
| | Original Course Date: January 16, 2020
| Approved Credit: : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ANCC: 0.80 hours Contact HourACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™ACPE: 0.75 hours Contact HourCoP: 0.00 hours Certificate of Participation
| MORE INFO |
|
|
 | Access Course
Experts discuss the latest research in the use of cancer immunotherapies.
This activity is intended for oncologists, pathologists, dermatologists, and other healthcare professionals who manage patients with cancer.
The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.
Approximate Time to Complete: 30 minutes
Credit Available: Dec. 19, 2018- Dec. 19, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 19, 2018
| Approved Credit: ABIM: 0.50 hours ABIM MOC Part 2 CreditsACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
| MORE INFO |
 | Access Course
Dr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).
This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).
The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.
Approximate Time to Complete: 1 hour
Course Available Beginning: Dec. 19, 2018 - Dec. 19, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 19, 2018
| Approved Credit: ANCC: 1 hour Contact HourABIM: 1 hour ABIM MOC Part 2 CreditsACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ACPE: 1 hour CEU
| MORE INFO |
 | Access Course
Dr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.
This activity is intended for oncologists, pulmonologists, and pathologists.
The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).
Approximate Time to Complete: 15 minutes
Credit Available: Dec. 18, 2018- Dec. 18, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 18, 2018
| Approved Credit: ABIM: 0.25 hours ABIM MOC Part 2 CreditsACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)™
| MORE INFO |
 | Access Course
The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.
This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).
The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.
Approximate Time to Complete: 30 minutes
Credit Available: Dec. 18, 2018 - Dec. 18, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 18, 2018
| Approved Credit: ANCC: 1 hour Contact HourABIM: 1 hour ABIM MOC Part 2 CreditsACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ACPE: 1 hour CEU
| MORE INFO |
 | Access Course
This article is for people who want to understand how biomarkers may affect their cancer treatment choices. It's also for their care partners, and others who want to learn more about the topic. The goal is to help you know what to discuss with your healthcare team about testing for biomarkers and what the results mean for your treatment.
You'll explore:
- What adjuvant therapy in melanoma is
- Who adjuvant therapy is recommended for
- The potential benefits of adjuvant therapy
- About side effects of adjuvant therapy
- Questions to ask your provider about adjuvant therapy
Available beginning: Dec. 18, 2018
Approximate Time to Complete: 30 minutes
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 18, 2018
| MORE INFO |
 | Access Course
Apply best practices to assess, treat, and educate patients with advanced NSCLC.
This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to build physician confidence in identifying and ordering appropriate evidence-based treatment regimens and providing patient education.
Approximate Time to Complete: 1 hour
Credit Available: Dec. 13, 2018- Dec. 13, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 13, 2018
| Approved Credit: ABIM: 1 hour ABIM MOC Part 2 CreditsACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
| MORE INFO |
 | Access Course
Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.
This activity is intended for oncologists, pulmonologists, and pathologists.
The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 9, 2018- Nov. 9, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: November 09, 2018
| Approved Credit: ABIM: 0.50 hours ABIM MOC Part 2 CreditsACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
| MORE INFO |
 |
Access the updated course, Introduction to Immunology – Third Edition.
Introduction to Immunology – Third Edition is a CME-, CPE-, CNE- and MOC-certified activity.
Please note that continuing education credit for Introduction to Immunology – Second Edition is only available through October 9, 2019.
Course Description
This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

Target Audience
This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Faculty
Christian M. Capitini, MD
Assistant Professor
University of Wisconsin Carbone Cancer Center
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
- Differentiate between the adaptive immune system and the innate immune system.
- Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system.
SITC Resources
Due to the rapidly-evolving field of cancer immunotherapy, some of the content in this course may be out of date. For current information from SITC on cancer immunotherapy, please reference the following resources:
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Continuing Education Information
Credit Available: September 28, 2018- October 9, 2019
Estimated time to complete activity: 1 hour
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-18-449-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Christian Capitini, MD: Consulting Fees at Nektar Therapeutics
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period September 28, 2018 through October 9, 2019 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please following the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for Introduction to Immunology – Second Edition.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Successfully complete the posttest with a passing score of 75% or better and the activity evaluation.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com.
| | Original Course Date: September 28, 2018
| Approved Credit: ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ANCC: 1 hour Contact HourACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™ACPE: 1 hour CEUCoP: 0.00 hours Certificate of Participation
| MORE INFO |
 | Access Course
Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.
This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Sep. 27, 2018- Sep. 27, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: September 27, 2018
| Approved Credit: ANCC: 0.50 hours Contact HourABIM: 0.50 hours ABIM MOC Part 2 CreditsACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
| MORE INFO |
 | Access Course
Learn about current and emerging immunotherapy options and how to monitor for and manage immune-related adverse events.
This activity is intended for nurses and nurse practitioners.
The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).
Approximate Time to Complete: 30 minutes
Credit Available: Sep. 26, 2018- Sep. 26, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: September 26, 2018
| Approved Credit: ANCC: 0.50 hours Contact HourABIM: 1 hour CEU
| MORE INFO |
 | Access Course
Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.
The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).
Approximate Time to Complete: 30 minutes
Credit Available: Sep. 19, 2018- Sep. 19, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: September 19, 2018
| MORE INFO |
 | The SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Clinical Trials - New Agents series contains four modules.
Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies
Peter Ellmark, PhD - Alligator Bioscience
Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents
James L. Gulley, MD, PhD, FACP - National Cancer Institute
Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors
Glen J. Weiss, MD - Western Regional Medical Center Inc.
Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance
Jason Williams, BS - University of Chicago
Target Audience
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
| | Original Course Date: August 16, 2018
| MORE INFO |
 | The SITC 2017 Microlearning: Toxicities Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Toxicities series contains three modules.
Module 1: Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis
Jennifer Wu, PhD - Northwestern University
Module 2: Pharmacological Management of irAEs
Nathan Dahl, PharmD, R.Ph, BCOP - Clovis Oncology
Module 3: Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool
Krista Marcello, BA - Clinical Care Options, LLC
Target Audience
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
| | Original Course Date: August 16, 2018
| MORE INFO |
 | The SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Clinical Trials - Novel Combinations series has three modules.
Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab
Jose Saro, MD - Roche Innovation Center Zurich
Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors
Zev Wainberg, MD - UCLA School of Medicine
Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
Douglas McNeel, MD, PhD - University of Wisconsin
Target Audience
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
| | Original Course Date: August 16, 2018
| MORE INFO |
 | The SITC 2017 Microlearning: Additional Topics Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The SITC 2017 Microlearning: Additional Topics series contains three modules.
Module 1: Genetically Modified T Cells for Solid Tumors
Stephen Gottschalk, MD - St. Jude Children's Research Hospital
Module 2: Improvement in Epitope Discovery
Catherine J. Wu, MD - Dana-Farber Cancer Institute
Module 3: Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors
Vinod Balachandran, MD - Memorial Sloan Kettering Cancer Center
Target Audience
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
| | Original Course Date: August 16, 2018
| MORE INFO |
 | The SITC 2017 Microlearning: Acquired Resistance Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Acquired Resistance Series contains three modules.
Module 1: Acquired Resistance Checkpoint Inhibitors in Lung Cancer
Katerina Politi, PhD - Yale School of Medicine
Module 2: Acquired Resistance to PD-1 Blockade in Melanoma
Antoni Ribas, MD, PhD - University of California, Los Angeles
Module 3: Acquired Resistance in Melanoma
Annette Paschen, MD - University Hospital Essen
Target Audience
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
| | Original Course Date: August 16, 2018
| MORE INFO |
 | Access the updated patient course, 2019 Patient Course: Understanding Cancer Immunotherapy – Fifth Edition.
This activity is based on the Patient Resource Guide, Understanding Cancer Immunotherapy 4th Edition (published in December 2017), designed for newly diagnosed and restaged cancer patients and their caregivers. This interactive activity takes a closer look at how the immune system works to fight against cancer, cancer immunotherapy treatment types and clinical trials.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Available beginning: May 22, 2018
Approximate Time to Complete: 30 minutes
This online patient education activity was produced with generous support from:
| | Original Course Date: May 22, 2018
| MORE INFO |
 | Access Course
Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.
This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 09, 2018 - Mar. 09, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: March 09, 2018
| Approved Credit: ANCC: 0.50 hours Contact HourACCME: 0.50 hours AMA PRA Category 1 Credit(s)™ABIM: 0.50 hours ABIM MOC Part 2 Credits
| MORE INFO |
 | Access Course
Follow the cases of 2 patients who developed immune-related adverse events following treatment with immune checkpoint blockade.
This activity is intended for oncologists, emergency medicine physicians, pulmonologists, and nurses.
The goal of this activity is to review strategies for identifying and managing adverse events associated with treatment with immune checkpoint blockade.
Approximate Time to Complete: 30 minutes
Credit Available: Feb. 28, 2018 - Feb. 28, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: February 28, 2018
| Approved Credit: ANCC: 0.50 hours Contact HourACCME: 0.50 hours AMA PRA Category 1 Credit(s)™ABIM: 0.50 hours ABIM MOC Part 2 Credits
| MORE INFO |
 | Access Course
Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.
This activity is intended for hematology/oncology specialists and pharmacists.
The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).
Approximate Time to Complete: 30 minutes
Credit Available: Feb. 27, 2018 - Feb. 27, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: February 27, 2018
| Approved Credit: ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™ABIM: 0.50 hours ABIM MOC Part 2 CreditsACPE: 0.50 hours CEU
| MORE INFO |
 | Access Course
This article is for people who have advanced head and neck cancer and want to learn about working with their care team to share information about treatment and side effects and get support.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Feb. 8, 2018
Developed through a partnership between SITC and Medscape.
| | Original Course Date: February 08, 2018
| MORE INFO |
 | Access Course
Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.
This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.
The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.
Approximate Time to Complete: 30 minutes
Credit Available: Dec. 24, 2018 - Dec. 24, 2019
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 17, 2017
| Approved Credit: ANCC: 0.50 hours Contact HourACCME: 0.50 hours AMA PRA Category 1 Credit(s)™ABIM: 0.50 hours ABIM MOC Part 2 CreditsACPE: 0.50 hours CEU
| MORE INFO |
|
|
 | Access Course
Experts discuss treatment strategies for one patient with recurrent HNSCC and one with locally advanced HNSCC.
This activity is intended for oncologists, pathologists, radiologists, surgeons, and other healthcare professionals who manage patients with head and neck cancer.
The goal of this activity is to discuss the emergence of immunotherapy in head and neck cancer along with treatment approaches with both curative and noncurative disease and clinical trials.
Approximate Time to Complete: 35 minutes
Course Available Beginning: Dec. 20, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 20, 2016
| MORE INFO |
 | Access Course
Watch as an oncologist, pharmacist, and nurse discuss challenges and best practices for working in a team environment.
This activity is intended for hematology and oncology specialists, nurses, advanced practice nurses and pharmacists.The goal of this activity is to identify interprofessional barriers and outline care team plans to achieve optimal outcomes for patients with non-small cell lung cancer (NSCLC).
Approximate Time to Complete: 35 minutes
Course Available Beginning: Dec. 16, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 16, 2016
| MORE INFO |
 | Access Course
This article is for people who’ve had treatment for kidney cancer that has now spread, called metastatic renal cell carcinoma (mRCC). It’s also for their care partners and others who want to learn more about the next treatment choices. The goal is to learn about all your treatment options so you can better decide with your care team what’s right for you.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Dec. 16, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 16, 2016
| MORE INFO |
 | Access Course
Imaging scans suggest this patient's melanoma has progressed, but has it? Watch this case to see how it develops.
This activity is intended for oncologists, dermatologists and pathologists.
The goal of this activity is to review the treatment options and patterns of progression in patients being treated for metastatic melanoma.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Dec. 7, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 07, 2016
| MORE INFO |
 | Access Course

Use a patient case to learn about managing adverse events with immunotherapy in patients with NSCLC.
This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to address how to start integrating immune checkpoint inhibitors into lung cancer treatment.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Dec. 6, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 06, 2016
| MORE INFO |
 | Access Course
Follow a patient with advanced adenocarcinoma to learn about the use and management of immune checkpoint inhibitors.
This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.
Approximate Time to Complete: 20 minutes
Credit Available: Dec. 6, 2016- Dec. 6, 2017
Developed through a partnership between SITC and Medscape.
| | Original Course Date: December 06, 2016
| MORE INFO |
 | Access Course
Read three articles that review immunotherapy treatment options in mesothelioma, small cell lung cancer, and non-small cell lung cancer.
This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to increase awareness of immunotherapy as a treatment option for extensive disease in thoracic cancers.
Approximate Time to Complete: 1 hour
Course Available Beginning: Nov. 30, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: November 30, 2016
| MORE INFO |
 | Access Course
Review appropriate treatment regimens for patients with metastatic melanoma.
This educational activity is intended for clinicians practicing in the areas of hematology-oncology, dermatology, pathology and lab medicine.
The goal of this activity is to build healthcare professionals' confidence in strategies for the individualized treatment of the patient with malignant melanoma and to ensure that updated guidelines and other emerging best practices are applied across a variety of clinical presentations.
Approximate Time to Complete: 1 hour
Course Available Beginning: Nov. 22, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: November 22, 2016
| MORE INFO |
 | Access Course
Dr. Tanguy Seiwert explores the emerging role for immunotherapy in head and neck cancer.
This activity is intended for oncologists, surgeons, and pathologists.
The goal of this activity is to discuss advances in the understanding of the role of the immune system in the head and neck cancer and strategies for using the immune system to treat head and neck cancer.
Approximate Time to Complete: 40 minutes
Course Available Beginning: Nov. 15, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: November 15, 2016
| MORE INFO |
 | Access Course
This activity is for people with non-small cell lung cancer who want to learn more about why, how, and when their care team may consider using immunotherapy as part of their treatment.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Nov. 8, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: November 08, 2016
| MORE INFO |
 | Access Course
This article is for people who are taking checkpoint inhibitor medicines for metastatic melanoma, their care partners, and others who want to learn about treatment side effects.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Nov. 8, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: November 08, 2016
| MORE INFO |
 | Access Course
Follow a patient with advanced squamous cell NSCLC to learn about the use and management of immune checkpoint inhibitors.
This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Oct. 21, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: October 21, 2016
| MORE INFO |
 | Access Course
A patient undergoing treatment for metastatic melanoma experiences some unusual symptoms. Watch this case to figure out what is going on.
This activity is intended for oncologists, dermatologists, and pathologists.
The goal of this activity is to review the treatment options and risks for immune-related adverse effects in patients being treated for metastatic melanoma.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Oct. 21, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: October 21, 2016
| MORE INFO |
 | Access Course
This activity is for people with non-small cell lung cancer (NSCLC) who want to learn more about how immunotherapy differs from chemotherapy.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Oct. 20, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: October 20, 2016
| MORE INFO |
 | Access Course

This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy. This activity is intended for oncologists, dermatologists, pathologists, and healthcare practitioners who care for patients with metastatic melanoma. The goal of this activity is to educate clinicians in the practical application of recently approved systemic.
Upon completion of this activity, participants will be able to:
Select opitmal therapy for patients with metastatic melanoma that harbors v600 BRAF mutations and for patients with wild-type BRAF. Explain the role of immunotherapy in patients with V600 BRAF mutation-positive metastatic melanoma. Outline a sequential treatment strategy for patients with V600 BRAF mutation-positive metastatic melanoma. Describe how to manage side effects and assess response to immunotherapy and targeted therapy in patients being treated for metastatic melanoma.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Oct. 19, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: October 19, 2016
| MORE INFO |
 | Access Course
Explore some of the main issues in the treatment of advanced RCC through two cases.
This activity is intended for oncologists, nephrologists, urologists, and other healthcare professionals who treat patients with advanced RCC.
The goal of this activity is to examine the options for second-line treatment of mRCC as well as strategies for working with the patient.
Approximate Time to Complete: 1 hour
Course Available Beginning: Sep. 21, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: September 21, 2016
| MORE INFO |
 | Access Course
Three articles examine the role of T cells in the anticancer immune response and how they are being used in therapy.
This activity is intended for hematologists and oncologists, pulmonologists and dermatologists.The goal of this activity is to explore advances being made in the harnessing of T cells for cancer immunotherapies.
Approximate Time to Complete: 1.25 hours
Credit Available: Sept. 15, 2016- Sept. 15, 2017
Developed through a partnership between SITC and Medscape.
| | Original Course Date: September 15, 2016
| MORE INFO |
 | Access Course
Learn how treatment of NSCLC with checkpoint inhibitors will affect your clinical outlook.
This activity is intended for pulmonologists, ID/HIV specialists, and pathologists who treat patients with lung cancer.
The goal of this activity is to provide pulmonologists perspectives on how immune checkpoint inhibitors may alter the diagnostic algorithm in individuals with suspected lung cancer.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Aug. 31, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: August 31, 2016
| MORE INFO |
 | Access Course
Drs. Weber, Luke, and Gangadhar discuss the latest updates to existing immunotherapies and examine where the future may lie.
This activity is intended for hematologists, oncologists, dermatologists, and pathologists.
The goal of this activity is to review the latest advances in immunotherapy for melanoma.
Approximate Time to Complete: 35 minutes
Course Available Beginning: Aug. 31, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: August 31, 2016
| MORE INFO |
 | Access Course

Experts discuss the basics of the immune system as well as existing and novel targets for cancer immunotherapy.
This activity is intended for hematologist/oncologists, pulmonologists, dermatologists, and other healthcare professionals who use cancer immunotherapies.
The goal of this activity is to review the role of the immune system in the development of tumors and research into the use of the immune system to fight tumors.
Approximate Time to Complete: 1 hour
Course Available Beginning: Aug. 24, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: August 24, 2016
| MORE INFO |
 | Access Course
Dr. Robert Ferris reviews the working of the immune system and the development of cancer.
This activity is intended for hematologists, oncologists, pulmonologists, dermatologist, immunologists, primary care providers, and other healthcare providers who use cancer immunotherapies.
The goal of this activity is to review the latest understanding of the relationship between the immune system and the tumor microenvironment as well as new immunotherapies in the management of patients with cancer.
Approximate Time to Complete: 30 minutes
Course Available Beginning: Aug. 24, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: August 24, 2016
| MORE INFO |
 | Access Course
Drs. Weiss, Borghaei, and Patel discuss the clinical data and practical implications for using checkpoint inhibitors to treat lung cancer.
This activity is intended for hematology and oncology specialists, pulmonologists and pathologists.
The goal of this activity is to provide insight on how recently published clinical trials on immune checkpoint inhibitors should be incorporated into practice.
Approximate Time to Complete: 40 minutes
Course Available Beginning: Aug. 24, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: August 24, 2016
| MORE INFO |
 | Access Course
Dr. Stephen Ansell discusses the emerging role of immunotherapy in the management of patients with Hodgkin lymphoma.
This activity is intended for hematologists, oncologists, pathologists, and other healthcare professionals who treat patients with Hodgkins lymphoma.
The goal of this activity is to discuss the latest understanding of the role of the immune system in the development of Hodgkin lymphoma as well as strategies for harnessing the immune
Approximate Time to Complete: 30 minutes
Course Available Beginning: Aug. 14, 2016
Developed through a partnership between SITC and Medscape.
| | Original Course Date: August 14, 2016
| MORE INFO |
|
|